Mobile News Releases

News Releases

News, events, updates, breakthroughs.

May 23, 2017 Daiichi Sankyo Cancer Enterprise Pipeline Data Showing Swift Progress in Precision Medicine for Breast Cancer to be Presented at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

May 01, 2017 Daiichi Sankyo, Inc. Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily SAVAYSA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

April 27, 2017 Daiichi Sankyo Announces 15 Billion Yen Manufacturing Investment to Support Acceleration of Antibody Drug Conjugate Portfolio

April 03, 2017 Daiichi Sankyo, Inc. Announces Sale of Pharmaceutical Packaging Plant in Bethlehem, PA

March 30, 2017 Daiichi Sankyo, Inc. Initiates ELIMINATE-AF Study Investigating Once-Daily SAVAYSA® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation

March 29, 2017 Daiichi Sankyo Cancer Enterprise Showcases New Data on Multiple Compounds at American Association for Cancer Research 2017 Annual Meeting

March 13, 2017 Daiichi Sankyo, Inc. Announces New Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at the ACC 66th Annual Scientific Session

March 06, 2017 Daiichi Sankyo, Inc. Initiates ENTRUST-AF PCI Study Investigating Once-Daily SAVAYSA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention with Stenting

February 17, 2017 Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in Second-Line Treatment of MET-Overexpressing Hepatocellular Carcinoma

February 03, 2017 Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Receive Complete Response Letter from FDA for New Drug Application for CL-108 (hydrocodone, acetaminophen, promethazine) Tablets for Oral Use

January 18, 2017 Daiichi Sankyo Initiates Phase 1/2 Study of Novel Antibody Drug Conjugate U3-1402 in Patients with HER3-Positive Metastatic or Unresectable Breast Cancer

December 12, 2016 Daiichi Sankyo and DarwinHealth Announce Strategic Partnership to Deploy a Quantitative Systems Biology Discovery Platform to Prioritize Daiichi Sankyo Cancer Enterprise Compounds for Development

December 05, 2016 Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology

December 01, 2016 U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer

November 30, 2016 Daiichi Sankyo Highlights Clinical Data of Two Novel Hematological Agents at the 58th Annual Meeting of the American Society of Hematology

November 07, 2016 Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily SAVAYSA® (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016

October 25, 2016 Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer

October 25, 2016 Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC Announce U.S. Licensing Agreement for MorphaBond™ Formulated with SentryBond™ Abuse-Deterrent Technology

October 21, 2016 ENLIVEN Phase 3 Study of Pexidartinib in Tenosynovial Giant Cell Tumor (TGCT) Will Continue to Completion Following Enrollment Discontinuation

October 12, 2016 Daiichi Sankyo and Dana-Farber Cancer Institute Announce Lung Cancer Research Collaboration

October 11, 2016 Daiichi Sankyo Announces First Patient Enrolled in Phase 3 QuANTUM-First Trial Investigating Quizartinib in Newly-Diagnosed FLT3-ITD+ Acute Myeloid Leukemia

October 09, 2016 Daiichi Sankyo Presents Late-Breaking Phase 1 Data for Novel Investigational HER2-Targeting Antibody Drug Conjugate DS-8201a in T-DM1 Pre-Treated Breast Cancer at the ESMO 2016 Congress

October 04, 2016 Daiichi Sankyo Announces New Strategic Immuno-Oncology Research Collaboration with AgonOx

September 28, 2016 Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific Antibody Collaboration

September 27, 2016 Daiichi Sankyo to Present at ESMO 2016 Late-Breaking Clinical Data for Novel HER2-Targeting Antibody Drug Conjugate in T-DM1 Pre-Treated Breast Cancer

September 06, 2016 Daiichi Sankyo Announces New Global Head of Development

August 24, 2016 Data from Phase 3b ENSURE-AF Study Investigating Once-Daily SAVAYSA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016

August 18, 2016 Daiichi Sankyo, Inc. Adds to Its Dynamic Team, Welcoming Leigh Ann Errico as the New Vice President of Human Resources for the U.S. Commercial Group

June 13, 2016 Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108

May 31, 2016 Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer (NSCLC)

April 18, 2016 Daiichi Sankyo, Inc. To Establish New U.S. Headquarters in Basking Ridge, New Jersey

April 01, 2016 Daiichi Sankyo Announces Appointment of Antoine Yver, MD, MSc to Global Head, Oncology Research and Development